MAPT and frontotemporal dementia: The study is primarily assessing safety and exploring any potential efficacy in this type of FTD by measuring CSF biomarkers, such as NfL and tau, as well as evaluating the effects of treatment on language impairment, behavior, cognition, and motor function.